Esperion Therapeutis.Inc. buy Bank of America Co.
Summary
This prediction ended on 16.06.24 with a price of €2.69. With a performance of 111.30% the BUY prediction by Bank_of_America_Co_ was a big success. Bank_of_America_Co_ has a follow-up prediction for Esperion Therapeutis.Inc., but this time predicts that Esperion Therapeutis.Inc. is a Sell. Bank_of_America_Co_ has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Esperion Therapeutis.Inc. | -3.114% | -3.114% | 60.072% |
iShares Core DAX® | -0.543% | 1.491% | 13.638% |
iShares Nasdaq 100 | -2.696% | -1.235% | 31.879% |
iShares Nikkei 225® | -2.863% | 2.491% | 12.078% |
iShares S&P 500 | -1.105% | 0.013% | 26.888% |
Comments by Bank_of_America_Co_ for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Current prediction by Bank_of_America_Co_ for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
20.06.24
20.06.25
22.07.24